Jeena Sikho Lifecare Ltd Q4 FY2026 Concall Summary

Key Takeaways

• FY26 delivered explosive scale with margin leap: Revenue rose 71% YoY to ₹801 cr while EBITDA margin expanded 1,360 bps to 44%, driven by higher patient volumes, richer product mix, and cost discipline across every line item.
• Q4 headline miss was entirely one-time accounting noise: A ~₹21 cr extraordinary charge from labour code provisions, ECL, leasehold adjustments under new auditor Grant Thornton, and loyalty points masked an otherwise stable operating quarter.
• A deliberate pivot from government to private pay is complete: Government sales were slashed from ₹118 cr to ₹36 cr to escape slow receivables, while private hospital sales grew 2.5x and retail nearly doubled, de-risking the revenue base.
• The product flywheel is just starting to spin: Nine OTC products launched within three months, with pregnancy, BP, sugar, kidney, liver, and depression medicines hitting the market in June-July; management expects the impact to show in 2-4 months.
• What to watch next quarter: Whether the 445 non-operational beds coming online in 3-4 months convert to revenue, the pace of product sales ramp from the June-July launches, and any clarity on the Entero tie-up that stalled.

The Q4 Miss: Accounting Reset, Not Operating Deterioration

• One-time charges totalled ~₹21 cr: ~₹7 cr from new labour code, ESOP, and performance bonuses; ~₹5 cr ECL provision; ~₹9 cr leasehold adjustment under Grant Thornton's first audit; ~₹1.25 cr loyalty points provision. Excluding these, operations were stable.
• Revenue recognition changed under the new auditor: Grant Thornton required advances to be booked only when the patient bill is generated and the patient leaves, shifting ~₹9 cr that would previously have landed in Q4 out of the quarter.
• Lease rent provision was a one-time catch-up, not a new recurring drag: The CFO clarified that leases spanning 3-5 years triggered a one-time Ind AS rental provision; going forward, the impact will be distributed equally quarter-to-quarter.
• A minor volume dip had a geopolitical trigger, not a demand one: Iran-US war panic in March caused roughly 250 preventive customers out of 40,000 advance bookings to defer visits; sick patients still came, and deferred customers are already returning, with Meerut's daily average rising from 240 to 316.
• Medicine sales dipped ₹3 cr QoQ because a planned tie-up stalled: Entero asked the company to bear expenses, so the partnership did not start; new products launched in May are expected to fill the gap in 2-4 months.

Manish Grover: "In such a large business with an INR800 crores turnover, seeing INR2 crores to INR4 crores up or down quarter-on-quarter doesn't matter to us. We are long-distance runners; we have to go further."

The Pivot to Private Pay and Retail

• Government sales were deliberately collapsed from ₹118 cr to ₹36 cr: Management cited credit getting stuck and late payments as the reason, choosing to shift volume to faster-paying private and retail channels.
• Private hospital sales grew 2.5x to ₹349 cr, retail nearly doubled to ₹415 cr: The shift de-risks receivables and aligns with the preventive and OTC product push, where retail is the natural channel.
• Services and products carry roughly the same EBITDA margin: Management declined to split margins, stating they differ by perhaps 1%, because product buyers become Panchakarma customers and vice versa, making cost allocation artificial.
• Revenue per bed sits at ₹4,650 on a total-bed-days basis: This compares with insurance rates of ₹8,800-9,200 and the Ayushman draft rate of ₹8,800-9,400, leaving a wide gap that formal insurance coverage could close.

Manish Grover: "Even if I occupy all beds, I am currently doing INR4,650 in revenue. If the Ayushman scheme comes and health insurance increases, then sir, look, the sky is the limit."

Product Portfolio: The OTC Pharmacy Bet

• Nine products launched, all within the last three months: Only one (Pet Yakrit Pleeha Shuddhi) is older than three months; second-wave products including Sea Buckthorn juice and Gut Care juice launched two months ago.
• Product sales already added ₹3 cr last month from the recent launches: Management expects the May launches to show their full impact in 2-4 months, with June and July bringing BP, sugar, kidney, liver, and depression medicines.
• A pregnancy product campaign launches this month: Couples will connect with Ayurveda for three months before conception; R&D and trials are complete, and 8-day and 14-day packages have been priced cheaply to drive adoption.
• New disease categories expand the addressable market beyond chronic care: The company is now targeting knee pain, back pain, Parkinson's, paralysis, depression, anxiety, and lack of sleep, alongside BP, diabetes, and asthma through new webinars.
• The Entero tie-up that was meant to accelerate product distribution did not materialize: Entero wanted the company to bear expenses; management walked away and is now relying on organic launches.

Manish Grover: "Even if 10% of the customers move towards me, sir, this turnover alone becomes at least INR250 crores a month. I didn't want to say this in your concall, the product that is being launched this month."

Capacity Build-Out: Beds, Centers, and Geographies

• Operational beds will rise from ~2,300 to 3,000 in 3-4 months: 445 beds are in active deployment, and all currently non-operational beds will be made operational within 3-5 months after being deliberately held back during the Iran-US uncertainty.
• A 7,000-10,000 bed vision sits behind a 3-5 year horizon: Management claims the homework is done, a doctor team is ready, and 2,000 beds can be added within 9-12 months whenever demand justifies it.
• New centers are proliferating across multiple cities: A large Lucknow hospital is being finalized this week, Ahmedabad work is ongoing, a new Patna property is being sought, a Kolkata property has been found, another Pune center is starting, and Mumbai beds are increasing.
• An ultra-luxury wellness center in Manali opens in July: 108 rooms, 22 villas, two helipads on a 40-acre forest, positioned as India's first forest bathing and forest meditation destination with Deodar trees.
• Preventive and curative centers are being separated from this month: Prevention patients will go to dedicated centers, curative patients to others, marking an operational split that mirrors the strategic pivot toward preventive healthcare.
• Seven colleges are available for acquisition: Management says any can be taken and made operational within 3-4 months, adding 2,000 beds in a year if needed.

The Preventive Healthcare Mission

• The company is explicitly repositioning as a preventive, not curative, brand: Management wants to build "an India that doesn't want to fall ill," framing the addressable market as the entire population rather than just the sick.
• Local disease camps reduce dependency on macro events: Separate managers now run small hospitals as individual units, running camps for knee pain, back pain, diabetes, and blood pressure to build steady local patient flow that is insulated from geopolitical shocks.
• A Swadeshi Health Card was launched in Q4 as a loyalty and referral tool: The card bundles referral benefits, diagnostic discounts, and service integration, with the trial phase ongoing.
• The Satkartar call center will be activated next month: A 1,400-person call center will be used for a new business idea, though specifics were not disclosed.
• TV appearances are building mass-market awareness: The company has appeared on "Laughter Chefs" twice, "MasterChef," and is currently on "Khatron Ke Khiladi," with a show shot outside India launching in August.

Manish Grover: "We will build such an India that doesn't want to fall ill. Because currently, the whole of India falls ill and then damages its GDP, damages its family."

Auditor, Governance, and the Narrative

• Grant Thornton's first audit was exhaustive: The report runs over 200 pages; GT visited at least 25 hospitals, sent staff as patients who got admitted, purchased items, and tested cash entries. The result was delayed to May 30 due to the extensive sampling.
• Management frames the auditor-driven changes as a necessary upgrade: Revenue recognition, lease accounting, and loyalty point provisions were all adjusted on GT's guidance, with the CEO stating practices must change when a large auditor is brought in.
• 190 research papers have been published, with seven Nobel Prize studies cited: Management is building a research backend that it expects will, within two years, draw patients from America, the UK, the Middle East, and Australia to India for treatment.
• The company wants to be judged on a multi-year horizon, not quarter-to-quarter: Management repeatedly asked investors to see the company as "a different kind of company" and "the future of India," explicitly requesting that more Ayurveda companies list to create a separate market.

Manish Grover: "Please, I request you all to see our company as a different kind of company and not see us quarter-on-quarter; see us as a long-term company as the future of India, as the forehead of India."

Guidance & Commitments

Key Metrics